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Abstract
Background and objective: Since 2013, a biennial rotavirus pattern has emerged in the Netherlands with alternating
high and low endemic years and a nearly 50% reduction in rotavirus hospitalization rates overall, while infant rotavirus
vaccination has remained below 1% throughout. As the rotavirus vaccination cost-effectiveness and risk-benefit ratio in
high-income settings is highly influenced by the total rotavirus disease burden, we re-evaluated two infant vaccination
strategies, taking into account this recent change in rotavirus epidemiology.
Methods: We used updated rotavirus disease burden estimates derived from (active) surveillance to evaluate (1) a
targeted strategy with selective vaccination of infants with medical risk conditions (prematurity, low birth weight,
or congenital conditions) and (2) universal vaccination including all infants. In addition, we added herd protection
as well as vaccine-induced intussusception risk to our previous cost-effectiveness model. An age- and risk-group
structured, discrete-time event, stochastic multi-cohort model of the Dutch pediatric population was used to estimate
the costs and effects of each vaccination strategy.
Results: The targeted vaccination was cost-saving under all scenarios tested from both the healthcare payer and
societal perspective at rotavirus vaccine market prices (€135/child). The cost-effectiveness ratio for universal vaccination
was €51,277 at the assumed vaccine price of €75/child, using a societal perspective and 3% discount rates. Universal
vaccination became cost-neutral at €32/child. At an assumed vaccine-induced intussusception rate of 1/50,000, an
estimated 1707 hospitalizations and 21 fatal rotavirus cases were averted by targeted vaccination per vaccine-induced
intussusception case. Applying universal vaccination, an additional 571 hospitalizations and < 1 additional rotavirus
death were averted in healthy children per vaccine-induced intussusception case.
Conclusion: While universal infant rotavirus vaccination results in the highest reductions in the population burden of
rotavirus, targeted vaccination should be considered as a cost-saving alternative with a favorable risk-benefit ratio for
high-income settings where universal implementation is unfeasible because of budget restrictions, low rotavirus
endemicity, and/or public acceptance.
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Introduction
In recent years, the Netherlands has seen an unexpected
change in rotavirus epidemiology, while infant rotavirus vac-
cination coverage (the vaccine has been licensed since 2006)
has remained below 1%. Annual epidemics were observed
until 2013; thereafter, an alternating pattern of high- and
low epidemic years emerged (Fig. 1). During low endemic
years, rotavirus detections in virological surveillance de-
creased by 58% (2014) and 52% (2016) compared to an aver-
age of the years before 2013, and a delayed start of rotavirus
seasons was observed [1, 2]. Similarly, general practice (GP)
consultation rates for acute gastroenteritis (AGE) during the
winter months in children under 5 years old were reduced
[3], and the prevalence of asymptomatic rotavirus observed
in daycare attendees was significantly lower in 2014 (preva-
lence rate 0.6%) compared to 2011–2013 (prevalence rate
6.8–11.2%) [4]. Rotavirus detections and seasonal GP con-
sultation rates during the alternating years 2015 and 2017
were comparable to pre-2014 numbers [3, 5]. Due to this
changing epidemiology, the overall incidence of rotavirus
disease in the Dutch pediatric population has reduced sub-
stantially. To our knowledge, a similar change in epidemic
pattern has not been observed in any other European coun-
try without a national infant rotavirus vaccination program.
Although the driving factors for this change in epidemic
pattern are currently unknown, it has been suggested that,
apart from a declining birth rate and temperature fluctua-
tions, rotavirus dynamics in the Netherlands may also be in-
fluenced by vaccination policies in neighboring countries
[6]. Universal rotavirus vaccination programs have been im-
plemented in all three neighboring countries of the
Netherlands (Belgium in 2006, Germany in 2013, the UK in
2013), with coverage varying between 78% and 94% [7–9].
Implementation in these countries was followed by a sus-
tained reduction in rotavirus detections of 44–75% [10].
This reduced circulation of rotavirus may have influenced
the number of rotavirus introductions into the Netherlands.
We previously evaluated the cost-effectiveness of in-
fant rotavirus vaccination in the Netherlands and con-
sidered three potential vaccination strategies: “no
vaccination,” “universal vaccination,” and “targeted vac-
cination” [11]. The targeted vaccination strategy is a se-
lective vaccination program, including only infants with
medical risk conditions predisposing to severe or com-
plicated rotavirus AGE, including prematurity, low birth
weight, and severe congenital pathology [10]. No deci-
sion has been made yet on the preferred strategy for the
Netherlands. Assuming the observed biennial pattern in
rotavirus epidemics represents a new epidemiological
equilibrium, a re-assessment of the national rotavirus
disease burden and the cost-effectiveness of each of
these infant rotavirus vaccination strategies is therefore
required to inform policy makers. In addition, it is now
widely recognized that rotavirus vaccination induces a
small but increased risk of intussusception (IS). Because
of this serious side effect, an evaluation of risk-benefit
ratios has become an integral part of the decision-making
process on rotavirus vaccination policy.
Our aim was to update our previous model-based
health economic evaluation of rotavirus vaccination in
the Netherlands by both taking into account the present,
lower endemic state, and expanding the analysis by
including risk-benefit calculations.
Methods
Updated rotavirus disease burden
The original economic evaluation [11] used data from
three observational studies conducted in the Netherlands:
(1) the Sensor cohort study on community AGE [12] and
(2) the Netherlands Institute of Primary Health Care
(NIVEL) study on AGE in primary care [13] were con-
ducted in 1999 and provided age-stratified data on AGE
incidence and the proportion rotavirus attributed; (3) the
RoHo study quantified rotavirus community-acquired
Fig. 1 Weekly number of rotavirus detections in sentinel laboratory surveillance (for 2017 only up to week 40)
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hospitalizations and nosocomial infections in children 0–
15 years old for the years 2006–2010 with separate esti-
mates for healthy children and those with medical risk
conditions [11, 14]. Incidence estimates by disease
category (rotavirus in the community, GP visits,
community-acquired hospitalizations, and nosocomial in-
fections) and by risk status (healthy vs medical risk group)
were derived from these studies and used as input for the
original cost-effectiveness model. To represent the average
rotavirus disease burden over the period 2013–2016, cov-
ering two high and two low epidemic seasons, we updated
these input parameters using the data sources and meth-
odology as discussed in the following sections.
Rotavirus community incidence
Virological laboratory surveillance in the Netherlands
collects weekly numbers of rotavirus detections from
17 to 21 sentinel laboratories serving primary care, hos-
pitals, and long-term care facilities [5]. Time series
analyses have confirmed that these surveillance data
correlate well with rotavirus disease activity in the
population [15, 16]. Rotavirus surveillance data were
used to scale the community incidence of rotavirus
AGE as originally measured in 1999 (Sensor study [12])
to the average for the years 2013–2016. We calculated
the scaling factor as follows: 1 minus ([mean]annual
rotavirus detections between 2013 and 2016/annual
rotavirus detections in 1999). We kept the original rota-
virus age distribution and the age-specific proportion of
cases visiting primary care, as no updated estimates
were available. The scaled incidence estimates were ap-
plied to the 2016 population size to obtain the annual
expected total number of community cases and GP
visits; see Table 1 [17].
Rotavirus hospitalizations
A similar approach was used to scale the annual number
of community-acquired and nosocomial rotavirus hospi-
talizations from the RoHo study (2006–2010) to the
average for the years 2013–2016. To calculate the scaling
factor, we used virological surveillance data on annual
rotavirus detections and annual AGE hospitalization
data derived from inpatient primary and secondary dis-
charge diagnoses collected by the Dutch National Med-
ical Registry (LMR, national coverage around 90%). The
anonymized discharge diagnoses were coded according
to the 9th International Classification of Diseases
(ICD-9) from 2001 up to 2012 and according to ICD-10
from 2013 onwards. Using an indirect method [15], the
proportion of AGE-coded hospitalizations attributable to
rotavirus (including community-acquired and nosoco-
mial infections) was calculated for each year in children
younger than 5 years. A scaling factor was then calcu-
lated from the indirectly estimated annual rotavirus
hospitalizations comparing the mean of 2006–2010
(RoHo-study years) to the mean of 2013–2016. This
scaling factor was applied to the mean annual number of
rotavirus hospitalizations used in the original model
(Table 1).
The proportion of rotavirus hospitalizations attribut-
able to nosocomial or community-acquired infections
and also the ratio of healthy vs risk-group children were
originally derived from the RoHo study. Proportions
were updated based on results from active AGE surveil-
lance conducted in 12 Dutch hospitals between Novem-
ber 2014 and November 2016 [18, 19]. Collected data
include age, sex, rotavirus presence in stool, type of in-
fection (community-acquired or nosocomial), and the
presence of medical risk conditions. As the active sur-
veillance only included children < 2 years of age, propor-
tions for older children were kept consistent to what
was found in the RoHo study.
Other parameter updates
Each model input parameter and assumption was checked
for potential updates by screening the literature and
checking available data from ongoing surveillance. As we
outline in this section, this yielded new and improved data
on the impact of rotavirus disease and vaccination, and we
updated our parameters accordingly.
A recent UK study estimated the quality-adjusted life year
(QALY) loss due to severe rotavirus AGE [20]. These esti-
mates were applied as QALY loss for community-acquired
rotavirus hospitalizations (Table 1).
For rotavirus episodes without medical care and those
requiring GP visits, we updated our previous estimates on
parental productivity losses due to work absence based on
results from a prospective household study on AGE
among 289 Dutch families with young children conducted
between January and May 2016 [21]. (See Table 1 and
Additional file 1 for details.)
All costs — healthcare costs, patient and family costs,
and productivity losses — were updated to 2016 cost
prices using Dutch consumer price indexes and recent
reference prices (Table 1) [22].
Herd protection as a result of infant rotavirus vaccin-
ation, where rotavirus AGE in unvaccinated children is
reduced, has been widely observed post-implementation
in high-income, high-coverage settings [23–27]. We
therefore incorporated herd-protection effects in our
base case for universal infant rotavirus vaccination. We
stratified herd-protection levels by age and by vaccinated
vs unvaccinated cohorts (Additional file 1: Table S1).
Unvaccinated age cohorts were assumed to be ineligible
for vaccination based on age at the time of implementa-
tion, but may still benefit from herd effects. The avail-
able studies on herd-protection levels used historical
pre-vaccination cohorts as a comparator in settings
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where annual rotavirus epidemics occurred [23–27]. To
account for the presence of a biennial epidemic pattern
in the current pre-vaccination setting in the
Netherlands, we lowered study estimates by 50% for our
analysis. This assumes that relevant reductions due to
herd effects only occur every other year. We assumed no
effect on adult rotavirus infections from any of the infant
vaccination strategies [11] and no herd effects for tar-
geted vaccination, as this would result in a maximum
vaccine coverage of 8% in the infant population [11].
Further parameter updates included changing the vac-
cination coverage for both targeted and universal vaccin-
ation from 88% (vaccine coverage Belgium [11]) to 86%
based on a recent assessment of willingness to vaccinate
among Dutch parents [28], changing the vaccine costs
for a targeted vaccination strategy to the current market
price of €135.32 per child [29] and changing the applica-
tion costs to €12.36 per dose [30]. Vaccine costs for a
universal vaccination within the national immunization
program were kept at €75 per child, which assumes that
tender processes will lower vaccine prices by almost 50%
[11, 31].
Intussusception
Our previous model [11] was extended to include the
risk of developing IS following rotavirus vaccination.
Based on the available literature, we assumed a
vaccine-induced IS rate of 1:50,000 [32–35], whereof
4.8% would result in complications ([36], Table 1). The
associated QALY loss for uncomplicated IS was 0.0037
[37], and costs were based on the average length of stay
(LOS; 2.11 days) for IS in the Netherlands (Table 1, see
Additional file 1 for details). Threefold higher estimates,
representing the 95% percentile of the LOS distribution,
were used for complicated IS cases (see Additional file 1
for details). Parental work loss was based on LOS, and
we assumed that an average caregiver works 16.4 h/
week, based on the mean weekly workhours among the
primary caregivers according to Statistics Netherlands in
2014 [38].
Model
The model has been described previously [11]; see Fig. 2.
In brief, we used an age- and risk-group structured,
discrete-time event, stochastic multi-cohort model of
the Dutch pediatric population. The model used separate
estimates for the number, and the costs of,
community-acquired and nosocomial rotavirus cases,
stratified by risk stratus into healthy vs medical risk con-
ditions, the latter qualifying for targeted vaccination
(Table 1). The effect of either targeted or universal infant
vaccination was modeled as a reduction in rotavirus
AGE and associated health outcomes in vaccinated and
non-vaccinated age cohorts between 0 and 15 years old,
stratified by risk status. Time steps of 1 month were
used for ages 0 to 11 months and time steps of 1 year
for ages 1 to 15. A time horizon of 20 years was used
with year 1 being the start of either vaccination
program.
Cost-effectiveness and risk-benefit analyses
The model was built in Microsoft Excel with the add-in
software @Risk, version 7.5 (Palisade). For all three vac-
cination strategies (“no vaccination,” “targeted vaccin-
ation,” and “universal vaccination”), the model estimates
the number of rotavirus cases in the population, GP
visits, hospitalizations, rotavirus-related deaths, QALYs,
and life years. The model further estimates the number of
vaccine-induced IS cases and associated QALYs. Net costs
(i.e., net social costs and net healthcare costs), life years
gained (LYG), and QALYs gained were calculated by sum-
ming all costs, life years, and QALYs over the 20-year time
Fig. 2 Rotavirus outcome tree and different healthcare paths considered in model. With permission from Bruijning-Verhagen et al. [11]
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horizon. For each simulation, 5000 runs were conducted
using Monte Carlo sampling, accounting for the uncer-
tainty of the model parameters (Table 1).
The incremental cost-effectiveness ratios (ICERs) were
calculated by dividing the net cost differences between
each vaccination strategy, compared to no vaccination,
by either QALYs gained or LYG. Our primary perspec-
tive was societal (i.e., including non-healthcare costs
such as caregiver work loss), and the healthcare payer
perspective was included in the sensitivity analysis. Costs
are expressed in 2016 euros. A discount rate of 3% was
used for both costs and effects [39].
Risk-benefit ratios were calculated by dividing the number
of severe outcomes averted by vaccination, which included
rotavirus hospitalizations or rotavirus fatal cases, by (1) the
estimated number of vaccine-induced IS cases and (2) the
estimated number of vaccine-induced complicated IS cases.
The calculated ratios were used to obtain the benefit per
vaccine-induced IS case and per vaccine-induced compli-
cated IS case, respectively. Risk-benefit ratios were calcu-
lated both for the total population and for each risk group,
since the risk of severe outcomes due to rotavirus differs be-
tween children with and without medical risk conditions.
Sensitivity and scenario analyses
Univariate sensitivity analysis was conducted to identify
critical parameters driving our results. In short, param-
eter variations included 25% lower and 25% higher rota-
virus hospitalization rates and hospitalizations costs;
vaccine-induced IS rates of 1:20,000 and 1:100,000 (base
case 1:50,000) [32–35], and IS complication rates of 0%
and 9.6% (base case 4.8%). We also included slightly
higher QALY losses based on the sensitivity analysis of
Marlow et al. (for hospitalizations 0.0039 vs 0.0030 and
for GP visits 0.0030 vs 0.0022) [20]) As caregiver
work-loss estimates for rotavirus AGE are influenced by
local employment conditions and parental leave plans,
they can vary substantially by country. Our sensitivity
analysis therefore also included 100% higher caregiver
productivity losses. Subsequently, we tested the impact
of old vs new parameter estimates including caregiver
work loss for mild and moderate rotavirus cases [4] and
QALY losses for hospitalized cases [11]. We applied
various discount rates: 2% and 4% for both costs and ef-
fects (3% in the baseline), as well as the Dutch discount
rates (1.5% for effects and 4% for costs [10]). Extensive
sensitivity analyses were conducted on vaccine costs to
determine the thresholds at which the vaccination strat-
egies would become cost-saving under base-case
assumptions.
Additionally, strategy-specific scenarios included the
following: a lower vaccination coverage of 75% for “tar-
geted vaccination” (baseline 86%); decreased or in-
creased herd protection, or no herd protection at all in
case of universal vaccination. Because a shift to a
biennial rotavirus epidemic pattern could theoretically
increase the average age of first infection as a result of
the reduced force of infection, we assessed the impact of
an “older” age when first infected. To this end, we simu-
lated scenarios where 50% or 75% of the 0–1 years old
patients with rotavirus from baseline were 1–2 years old
instead, and consequently had lower probabilities of
seeking medical care, both GP and hospitalization. Fi-
nally, an “alternative universal vaccination” scenario was
also analyzed where we assumed that “universal vaccin-
ation” would be recommended, but not covered by the
publicly funded national immunization program. In-
stead, vaccines would be individually purchased for each
infant with or without partial reimbursement from
health insurance. For this scenario, we assumed a cover-
age of 60%, no herd protection due to the lower cover-
age, and the actual market price (i.e., €135.32/child). For
more details see also Additional file 2: Tables S2 and S3.
Results
The updated rotavirus disease burden estimated a reduc-
tion in the number of rotavirus AGE episodes in the
Netherlands by 13% compared to 1999, and in the num-
ber of hospitalizations by 45% compared to 2006–2010.
The 2014–2016 active surveillance data identified a
somewhat higher proportion of children with medical
risk conditions (26% vs 16%) among those < 2 years of
age hospitalized for rotavirus and a higher proportion of
nosocomial infections (28% vs 11%) compared to the
RoHo study [11].
Without vaccination and over a 20-year time horizon,
an estimated 1.25 million rotavirus AGE episodes
(62,500 annually), 54,000 hospitalizations (2700 annu-
ally), and 110 fatal rotavirus cases (5.5 annually) in chil-
dren 0–15 years old would occur in the Netherlands,
resulting in 2597 QALYs lost (130 annually) or 1309 life
years lost (65.45 annually), and in societal costs of €180
million (Є9 million annually; see Table 2).
We first compared targeted vaccination to no vaccin-
ation over a 20-year time horizon. With annual vaccin-
ation costs of €0.64 million, targeted vaccination would
avert on average 43,000 rotavirus AGE episodes and 99
fatal cases, and would induce 4.6 IS cases, of which 0.22
would be complicated cases. The targeted vaccination
strategy would result in 1139 QALYs gained and €17
million savings (Table 2). Targeted vaccination was
cost-saving in all simulations (Fig. 3) and remained
cost-saving in all conducted sensitivity analyses (Fig. 4a
and Additional file 2: Table S2).
We then compared the no vaccination strategy to univer-
sal vaccination, which would cost €15 million annually.
Over a 20-year time horizon universal vaccination would
avert 665,000 rotavirus AGE episodes and 103 fatal cases
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and would induce 58.4 IS cases, of which 2.8 would be
complicated. Universal vaccination would result in 1907
QALYs gained and €98 million additional costs (Table 2) at
an ICER of €51,280/QALY gained (Fig. 2 and Additional file
2: Table S3). When universal vaccination was compared to
targeted vaccination, the ICER increased to €149,280/QALY
gained. Sensitivity analyses revealed that vaccine costs,
presence and level of herd protection, the perspective
chosen (i.e., healthcare costs only vs societal costs),
the number of annual rotavirus hospitalizations, the
costs per hospitalization, older age at first infection,
and productivity losses were most influential on
cost-effectiveness results (Figs. 4, 5 and Additional file
2: Table S3 and Figure S1). Under base-case assump-
tions and using a societal perspective, universal vac-
cination would become cost-saving at vaccine costs of
€32 per child when compared to a strategy with no
vaccination, or at €24.5 per child when compared to
a strategy with targeted vaccination. The alternative
universal vaccination scenario, where the vaccine
would not be covered by the publicly funded national
immunization program but purchased individually at
market prices, was not considered cost-effective at an
ICER of €119,191/QALY (95% credibility interval (CI)
€70,488/QALY–€244,692/QALY) (see Fig. 3 and Add-
itional file 2: Table S3).
Vaccination averts fatal rotavirus cases and hospitalization
(benefits), but at the costs (risk) of inducing IS cases. The
risk-benefit ratio differed by health status of the vaccinated
child (Table 3). Among infants with medical risk conditions,
we estimated a benefit of 21 prevented fatal rotavirus cases
and 1707 prevented rotavirus hospitalizations for every
vaccine-induced IS case. In healthy children the estimated
risk-benefit ratio resulted in 0.05 prevented fatal cases and
571 hospitalized cases for every vaccine-induced IS case.
Discussion
Our results show that, in a high-income and relatively low
rotavirus endemic setting, targeted rotavirus vaccination
of infants with medical risk conditions is a cost-saving
strategy and has the most favorable risk-benefit ratio. This
finding remains robust in all of our sensitivity analyses.
This strategy would also nearly eliminate rotavirus-related
mortality in high-income settings, where fatal rotavirus
cases among otherwise healthy children are extremely
rare. Yet, the impact of targeted vaccination on the rota-
virus disease burden in the pediatric population is limited,
with only a 3.4% reduction in AGE episodes and a 14.7%
reduction in hospitalizations (Table 2).
Universal rotavirus vaccination has the potential to re-
duce the population rotavirus disease burden in children by
> 50% and avert nearly 75% of hospitalizations (Table 2).
However, in a low-endemic setting and at assumed vaccine
costs of €75 per child, the ICER for universal rotavirus vac-
cination at €51,280/QALY for the societal perspective and
at €72,021/QALY for the healthcare perspective is not
considered a cost-effective intervention according to
most internationally accepted willingness-to-pay thresholds
[40–42]. Further reductions in vaccine prices are therefore
needed to improve cost-effectiveness. Universal vaccination
could become cost-saving when vaccine costs are reduced
to €32 per child or less. Importantly, even in a low-endemic
setting, the risk-benefit ratio for healthy children vaccinated
under a universal vaccination strategy can still be
Fig. 3 Cost-effectiveness plane for targeted vaccination (depicted in red) and universal vaccination (depicted in green) using a societal perspective
and a 3% discount rate
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considered favorable at 571 averted hospitalizations for
every vaccine-induced case of IS.
Our analysis also showed that the alternative universal
vaccination scenario, i.e., no publicly funded program
but vaccines individually purchased, is the least favorable
strategy due to higher vaccine costs per child (no price
reductions generated through tender processes) and ab-
sence of herd protection because of moderate vaccine
uptake. Yet, this or comparable strategies are currently
in use in several high- or middle-income countries [43].
Health authorities may therefore wish to reconsider one of
the alternative, more cost-effective vaccination strategies.
a
b
Fig. 4 Tornado diagram showing one-way and multi-way sensitivity and scenario analyses results for a a targeted vaccination strategy and b a
universal vaccination strategy
Note1: The x-axis shows the effect of changes in selected variables on the mean incremental cost-effectiveness ratio (ICER) for the base-case
taking a societal perspective. The y-axis shows the model parameter that was varied. The bars indicate the mean change in the ICER caused by
changes in the value of the indicated variable holding all other parameters similar, whereby a blue bar indicates a lower value of the selected
variable(s) as in the baseline and a red bar a higher value of the selected variable(s). Sensitivity analyses with less than 5% changes are not
shown. Detailed results are presented in Table S2 in Additional file 2 for targeted vaccination and in Table S3 in Additional file 2 for universal
vaccination.
Note2: All scenarios for targeted vaccination were cost-saving and health gaining. This results in negative ICERs.
*Some of the sensitivity analyses were only applicable to universal vaccination (i.e. alternative universal vaccination strategy), and others were
only to target vaccination (i.e. lower coverage in the target population).
**No S.A. on vaccine price was performed for targeted vaccination as this was already cost-saving at the current market price; No S.A. on herd
immunity, as a population vaccine coverage of 7% will not induce herd protection
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Healthcare budget restrictions and prioritization may be
an important reason why a publicly funded universal vac-
cination program is unfeasible. In this situation, a publicly
funded targeted vaccination program can form a suitable
alternative, as it results in cost savings both from the soci-
etal and healthcare payer perspective, while protecting the
most vulnerable infants. Concerns about vaccine safety of
the currently licensed vaccines and public acceptance may
be another reason for not implementing universal vaccin-
ation. For instance, in France several reports on severe
and even fatal IS cases following rotavirus vaccination re-
sulted in public concern and the decision by health au-
thorities to withdraw the recommendation for routine
infant rotavirus vaccination [44]. A recommendation for
targeted vaccination could offer an acceptable solution be-
cause of the more favorable risk-benefit ratio.
Our study has several limitations. The model input was
largely based on epidemiological data as well as healthcare
and non-healthcare cost estimates from the Netherlands.
Differences in rotavirus endemicity, population demo-
graphics, caregiver employment, and cost prices may limit
the generalizability of our findings to other high-income
settings. However, we have performed extensive sensitivity
analyses to evaluate the robustness of our ICER estimates
and the most influential parameters. As targeted vac-
cination remained cost-saving under all scenarios
tested, we are confident that this strategy will be
cost-saving to other high-income settings. The ICER for
universal vaccination, however, may be more variable,
and for some high-income countries it may be better
represented by one of the alternative scenarios from
our sensitivity analysis.
Fig. 5 Mean ICER (cost per QALY gained) for universal vaccination vs no vaccination (green line/dots), and for universal vaccination vs targeted vaccination
(black line/dots) using a societal perspective and assuming a discount rate of 3%, for different vaccine costs. Results are also presented in Table S3 in
Additional file 2 (universal vaccination vs no vaccination) and in Table S4 in Additional file 2 (universal vaccination vs targeted vaccination)
Table 3 Risk-benefit ratios for rotavirus vaccination
Induced IS: prevented
fatal cases
Induced IS: prevented
hospitalized cases
Induced complicated IS:
prevented fatal cases
Induced complicated IS:
prevented hospitalized cases
All children
Targeted vaccination 1:21 (1:12–1:33) 1:1707 (1:1494–1:1920) 1:445 (1:244–1:691) 1:35,564 (1:31,126–1:39,995)
Universal vaccination 1:1.8 (1:1.0–1:2.8) 1:685 (1:603–1:767) 1:37 (1:20–1:59) 1:14,267 (1:12,566–1:15,974)
Targeted group
Targeted vaccination 1:21 (1:12–1:33) 1:1707 (1:1494–1:1920) 1:445 (1:244–1:691) 1:35,564 (1:31,126–1:39,995)
Universal vaccination 1:22 (1:12–1:34) 1:2012 (1:1773–1:2252) 1:455 (1:250–1:706) 1:41,913 (1:36,942–1:46,921)
Healthy children
Targeted vaccination NA NA NA NA
Universal vaccination 1:0.05 (1:0.00–1:0.16) 1:571 (1:503–1:639) 1:1.0 (1:0.03–1:3.24) 1:11,896 (1:10,475–1:13,319)
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Our model did not include dynamic simulation of herd
effects following introduction of universal vaccination.
Given the unusual pre-vaccination biennial rotavirus pat-
tern in the Netherlands, observations on herd-protection
levels from other countries may not be representative.
Therefore, we chose to lower the herd-protection
estimates extracted from studies in Europe and North
America by 50% for our analysis. We considered this the
most likely scenario, but the accuracy of these adjusted es-
timates remains uncertain. Our sensitivity analysis showed
that a 50% change in herd effects from baseline would re-
sult in a 15% change in ICER. Another limitation of our
static, rather than a dynamic model, is that we could not
explore how universal rotavirus vaccination affects the
timing and pattern of rotavirus epidemic peaks. Sudden
spikes in incidence put additional pressure on hospital
capacity, and this may be especially relevant if these coin-
cide with circulation of respiratory viruses in winter
months. The periodicity and timing of rotavirus epidemics
may therefore be important for bed capacity planning.
Available rotavirus dynamic models so far suggest that
high-coverage rotavirus vaccination in temperate climates
results in a biannual pattern and a shift of the epidemic
peak to April/May [45].
Finally, it is currently uncertain whether the biennial
rotavirus pattern in the Netherlands will be sustained in
future years. If conditions affecting rotavirus epidemi-
ology change in the future, disease levels could return to
those pre-2014. Naturally, this would change the ICERs
for the different vaccination strategies analyzed and the
threshold for cost-saving vaccine prices.
Conclusion
While universal infant rotavirus vaccination results in
the highest reductions in the population burden of
rotavirus, targeted vaccination should be considered
as a cost-saving alternative with the most favorable
risk-benefit ratio for high-income settings where universal
implementation is unfeasible for reasons of budget
restrictions, low rotavirus endemicity, and/or public
acceptance.
Additional files
Additional file 1: Model input data. (DOCX 27 kb)
Additional file 2: Additional results. (DOCX 71 kb)
Abbreviations
AGE: Acute gastroenteritis; CI: Credibility interval; GP: General practice;
ICER: Incremental cost-effectiveness ratio; IS : Intussusception; QALY: Quality-
adjusted life year
Acknowledgements
We thank Wilfrid van Pelt for providing historical data on rotavirus detections
in the Netherlands from virological surveillance.
Funding
PB-V has received funding from the Netherlands Organization for Health Research
and Development for conduct of the RotaFam study (ZonMw number
016.166.158) and Risk-Group Infant Vaccination Against Rotavirus (RIVAR) study
(ZonMw number 80–83600–98-20129).
Availability of data and materials
All relevant data are within the paper. Further details are available from the
last author on reasonable request.
Authors’ contributions
PB-V and MJJM developed the model structure, interpreted the results, and
wrote the first draft of the paper. JvD and RP collected the data. RvG was
involved in drafting the manuscript, interpreting the data, and critically
revising the manuscript for important intellectual content. JV, DK, and HdM
were involved in interpreting the data and critically revising the manuscript
for important intellectual content. MJJM performed the model analysis. All
authors read and approved the final manuscript. PB-V and MJJM had full ac-
cess to all of the data in the study and take responsibility for the integrity of
the data and the accuracy of the data analysis.
Ethics approval and consent to participate
Not applicable
Consent for publication
Not applicable
Competing interests
PB-V has received a research grant from GlaxoSmithKline for an investigator-
initiated study on rotavirus vaccination in medical risk infants. The other authors
declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Received: 23 November 2017 Accepted: 24 July 2018
References
1. Hahne S, Hooiveld M, Vennema H, van Ginkel A, de Melker H, Wallinga J,
van Pelt W, Bruijning-Verhagen P. Exceptionally low rotavirus incidence in
the Netherlands in 2013/14 in the absence of rotavirus vaccination. Euro
Surveill. 2014;19(43).
2. Verberk JDM, Bruijning-Verhagen P, de Melker HE. Rotavirus in the
Netherlands; background information for the Health Council. In: RIVM
Report. Bilthoven: National Institute of Public Health and the Environment;
2017. p. 1–70.
3. National Institute for Public Health and the Environment. State of Infectious
Diseases in the Netherlands, 2016. http://www.rivm.nl/dsresource?objectid=
bce6439b-ce72-49d3-b7ed-e0c42348c8c5&type=pdf&disposition=inline.
4. Enserink R, Scholts R, Bruijning-Verhagen P, Duizer E, Vennema H, de Boer R,
Kortbeek T, Roelfsema J, Smit H, Kooistra-Smid M, et al. High detection rates
of enteropathogens in asymptomatic children attending day care. PLoS
One. 2014;9(2):e89496.
5. Rijksinstituut voor Volksgezondheid en Milieu. RIVM Virologische
Weekstaten, Open Rapportages [http://www.rivm.nl/Onderwerpen/V/
Virologische_weekstaten/Rapportages/Open_rapportages_virologische_
weekstaten/Virologische_uitslagen_per_week_sinds_2006_grafieken].
6. van Gaalen RD, van de Kassteele J, Hahne SJM, Bruijning-Verhagen P,
Wallinga J. Determinants of rotavirus transmission: a lag nonlinear time
series analysis. Epidemiology. 2017;28(4):503–13.
7. Braeckman T, Theeten H, Lernout T, Hens N, Roelants M, Hoppenbrouwers K, Van
Damme P. Rotavirus vaccination coverage and adherence to recommended age
among infants in Flanders (Belgium) in 2012. Euro Surveill. 2014;19(20:pii=20806)
8. Rieck T, Wichmann O, Siedler A. Aktuelles aus der KV-Impfsurveillance;
Impfquoten der rotavirus-, Masern-, HPV- und Influenza-Impfung in
Deutschland. Epidemiologisches Bulletin. 2017;2017(1)
9. Public Health England. National rotavirus immunisation programme update:
preliminary vaccine coverage for England, February 2016 to July 2016. In:
Infection Report. vol. 10 Number 32: Health Protection Report; 2016.
Bruijning-Verhagen et al. BMC Medicine  (2018) 16:168 Page 13 of 15
10. de Hoog MLA, Vesikari T, Giaquinto C, Huppertz HI, Martinon-Torres F,
Bruijning-Verhagen P. Report of the 5th European expert meeting on rotavirus
vaccination (EEROVAC). Hum Vaccin Immunother. 2018;14(4):1027–34.
11. Bruijning-Verhagen P, Mangen MJ, Felderhof M, Hartwig NG, van Houten M,
Winkel L, de Waal WJ, Bonten MJ. Targeted rotavirus vaccination of high-risk
infants; a low cost and highly cost-effective alternative to universal
vaccination. BMC Med. 2013;11:112.
12. de Wit MA, Koopmans MP, Kortbeek LM, Wannet WJ, Vinje J, van Leusden F,
Bartelds AI, van Duynhoven YT. Sensor, a population-based cohort study on
gastroenteritis in the Netherlands: incidence and etiology. Am J Epidemiol.
2001;154(7):666–74.
13. de Wit MA, Koopmans MP, Kortbeek LM, van Leeuwen NJ, Bartelds AI, van
Duynhoven YT. Gastroenteritis in sentinel general practices, The
Netherlands. Emerg Infect Dis. 2001;7(1):82–91.
14. Bruijning-Verhagen P, Sankatsing V, Kunst A, van den Born C, Bleeker E,
Thijsen S, Ijzerman EP, van der Velden VH, Bonten MJ. Rotavirus-related
hospitalizations are responsible for high seasonal peaks in all-cause pediatric
hospitalizations. Pediatr Infect Dis J. 2012;31(12):e244–9.
15. National Institute for Public Heath and the Environment. The National
Immunisation Programme in the Netherlands: developments in 2009
[http://www.rivm.nl/bibliotheek/rapporten/210021012.pdf].
16. Schurink-van’ t Klooster TM, de Melker HEE. The national immunisation
programme in the Netherlands: surveillance and developments in 2015-
2016. Bilthoven: Rijksinstituut voor Volksgezondheid en Milieu; 2016.
17. Mangen MJ, van Duynhoven YT, Vennema H, van Pelt W, Havelaar AH,
de Melker HE. Is it cost-effective to introduce rotavirus vaccination in the
Dutch national immunization program? Vaccine. 2010;28(14):2624–35.
18. van Dongen F, Schuurman R, Bonten MJM, Study-Group ObotR. Rotavirus
hospitalizations in the absence of rotavirus vaccine in 2015–2016 in the
Netherlands. In: 5th European Expert Meeting on Rotavirus Vaccination:
March 20-22nd, 2017 2017; Utrecht; 2017. p. 85.
19. RIVAR-project: Risk-Group Infant Vaccination Against Rotavirus. [http://portal.
juliuscentrum.nl/research/nl-NL/cohortsandprojects/cohortsprojects/rivar.aspx].
20. Marlow R, Finn A, Trotter C. Quality of life impacts from rotavirus gastroenteritis
on children and their families in the UK. Vaccine. 2015;33(39):5212–6.
21. Quee F, de Hoog MLA, Schuurman R, Bruijning-Verhagen P. A comparison
of incidence, transmission and burden of norovirus and rotavirus infections
among young families in the Netherlands. In: 5th European Expert Meeting
on Rotavirus Vaccination: March 20-22nd, 2017 2017; Utrecht; 2017. p. 83–4.
22. ZIN. Kostenhandleiding: Methodologie van kostenonderzoek en
referentieprijzen voor economische evaluaties in de gezondheidszorg.
Diemen: Zorginstituut Nederland (ZIN); 2015. Geactualiseerde versie 2015
23. Prelog M, Gorth P, Zwazl I, Kleines M, Streng A, Zlamy M, Heinz-Erian P,
Wiedermann U. Universal mass vaccination against rotavirus: indirect effects
on rotavirus infections in neonates and unvaccinated young infants not
eligible for vaccination. J Infect Dis. 2016;214(4):546–55.
24. Atchison CJ, Stowe J, Andrews N, Collins S, Allen DJ, Nawaz S, Brown D,
Ramsay ME, Ladhani SN. Rapid declines in age group-specific rotavirus
infection and acute gastroenteritis among vaccinated and unvaccinated
individuals within 1 year of rotavirus vaccine introduction in England and
Wales. J Infect Dis. 2016;213(2):243–9.
25. Krishnarajah G, Demissie K, Lefebvre P, Gaur S, Sheng Duh M. Clinical and
cost burden of rotavirus infection before and after introduction of rotavirus
vaccines among commercially and Medicaid insured children in the United
States. Hum Vaccin Immunother. 2014;10(8):2255–66.
26. Kaufman HW, Chen Z. Trends in laboratory rotavirus detection: 2003 to
2014. Pediatrics. 2016;138(4):e20161173.
27. Sabbe M, Berger N, Blommaert A, Ogunjimi B, Grammens T, Callens M, Van
Herck K, Beutels P, Van Damme P, Bilcke J. Sustained low rotavirus activity
and hospitalisation rates in the post-vaccination era in Belgium, 2007 to
2014. Euro Surveill. 2016;21
28. Veldwijk J, Lambooij MS, Bruijning-Verhagen PC, Smit HA, de Wit GA.
Parental preferences for rotavirus vaccination in young children: a discrete
choice experiment. Vaccine. 2014;32(47):6277–83.
29. Zorginstituut Nederland. Medicijnkosten.nl. [https://www.medicijnkosten.nl/
databank?artikelId=7083&hoeveelheid=1,00].
30. Nederlandse Zorgautoriteit. Toedieningskosten per vaccinatie - H006:
neventarief 0 tot 5 jarige - Nederlandse Zorgautoriteit Rekenstaat 2014
tariefbeschikking. Utrecht: Nederlandse Zorgautoriteit; 2014.
31. Rozenbaum MH, Mangen MJ, Giaquinto C, Wilschut JC, Hak E, Postma MJ,
Consensus Group on Dutch Rotavirus V. Cost-effectiveness of rotavirus
vaccination in the Netherlands; the results of a consensus model. BMC
Public Health. 2011;11:462.
32. Leino T, Ollgren J, Stromberg N, Elonsalo U. Evaluation of the
intussusception risk after pentavalent rotavirus vaccination in Finnish infants.
PLoS One. 2016;11(3):e0144812.
33. Stowe J, Andrews N, Ladhani S, Miller E. The risk of intussusception
following monovalent rotavirus vaccination in England: a self-controlled
case-series evaluation. Vaccine. 2016;34(32):3684–9.
34. Rha B, Tate JE, Weintraub E, Haber P, Yen C, Patel M, Cortese MM,
DeStefano F, Parashar UD. Intussusception following rotavirus vaccination:
an updated review of the available evidence. Expert Rev Vaccines. 2014;
13(11):1339–48.
35. Oberle D, Jenke AC, von Kries R, Mentzer D, Keller-Stanislawski B. Rotavirus
vaccination: a risk factor for intussusception? Bundesgesundheitsblatt
Gesundheitsforschung Gesundheitsschutz. 2014;57(2):234–41.
36. Palupi-Baroto R, Lee KJ, Carlin JB, Bines JE. Intussusception in Australia:
epidemiology prior to the introduction of rotavirus vaccine. Aust N Z J
Public Health. 2015;39(1):11–4.
37. Reyes JF, Wood JG, Beutels P, Macartney K, McIntyre P, Menzies R, Mealing N,
Newall AT. Beyond expectations: post-implementation data shows rotavirus
vaccination is likely cost-saving in Australia. Vaccine. 2017;35:345–52.
38. Mangen MJ, Bouwknegt M, Friesema IH, Haagsma JA, Kortbeek LM, Tariq L,
Wilson M, van Pelt W, Havelaar AH. Cost-of-illness and disease burden of food-
related pathogens in the Netherlands, 2011. Int J Food Microbiol. 2015;196:84–93.
39. Tan-Torres Edejer T, Baltussen R, Adam T, Hutubessy R, Acharya A, Evans DB,
Murray CJL. WHO guide to cost-effectiveness analysis. Geneva: World Health
Organization; 2003.
40. National Institute for Health and Care Excellence. Guide to the methods of
technology appraisal 2013. [https://www.nice.org.uk/process/pmg9/chapter/
the-appraisal-of-the-evidence-and-structured-decision-making].
41. Cleemput I, Neyt M, Thiry N, De Laet C, Leys M. Threshold values for
costeffectiveness in health care health technology assessment (HTA).
Brussels: Belgian Health Care Knowledge Centre; 2008.
42. Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness—the
curious resilience of the $50,000-per-QALY threshold. N Engl J Med. 2014;
371(9):796–7.
43. Parez N, Giaquinto C, Du Roure C, Martinon-Torres F, Spoulou V, Van
Damme P, Vesikari T. Rotavirus vaccination in Europe: drivers and barriers.
Lancet Infect Dis. 2014;14(5):416–25.
44. Publique HCdlS. Infections à rotavirus : suspension des recommandations
de vaccination des nourrissons [rotavirus infections; recommendation for
infant vaccination suspended]. In: Avis et rapports de HCSP. Paris: Haut
Conseil de la Sante Publique (HCSP); 2015. p. 1–5.
45. Pitzer VE, Atkins KE, de Blasio BF, Van Effelterre T, Atchison CJ, Harris JP,
Shim E, Galvani AP, Edmunds WJ, Viboud C, et al. Direct and indirect effects
of rotavirus vaccination: comparing predictions from transmission dynamic
models. PLoS One. 2012;7(8):e42320.
46. Centraal Bureau voor de Statistiek. Levensverwachting; geslacht, leeftijd (per
jaar en periode van vijf jaren). [http://statline.cbs.nl/Statweb/publication/
?DM=SLNL&PA=37360ned&D1=3&D2=a&D3=a&D4=95&HDR=G1,T&STB=
G2,G3&VW=T].
47. Global Health Data Exchange. Perinatal care in the Netherlands 2008. 2008.
48. Brisson M, Sénécal M, Drolet M, Mansi JA. Health-related quality of life lost
to rotavirus-associated gastroenteritis in children and their parents: a
Canadian prospective study. Pediatr Infect Dis J. 2010;29(1):73–5.
49. Jit M, Mangen MJ, Melliez H, Yazdanpanah Y, Bilcke J, Salo H, Edmunds WJ,
Beutels P. An update to “The cost-effectiveness of rotavirus vaccination:
comparative analyses for five European countries and transferability in
Europe”. Vaccine. 2010;28(47):7457–9.
50. Friesema IH, Lugner AK, van Duynhoven YT, Group GEW. Costs of gastroenteritis
in the Netherlands, with special attention for severe cases. Eur J Clin Microbiol
Infect Dis. 2012;31(8):1895–900.
51. van den Brandhof WE, De Wit GA, de Wit MA, van Duynhoven YT. Costs of
gastroenteritis in the Netherlands. Epidemiol Infect. 2004;132(2):211–21.
52. Haagsma JA, Geenen PL, Ethelberg S, Fetsch A, Hansdotter F, Jansen A,
Korsgaard H, O'Brien SJ, Scavia G, Spitznagel H, et al. Community incidence
of pathogen-specific gastroenteritis: reconstructing the surveillance pyramid
for seven pathogens in seven European Union member states. Epidemiol
Infect. 2013;141(8):1625–39.
53. van der Valk ME, Mangen MJ, Leenders M, Dijkstra G, van Bodegraven AA,
Fidder HH, de Jong DJ, Pierik M, van der Woude CJ, Romberg-Camps MJ,
Bruijning-Verhagen et al. BMC Medicine  (2018) 16:168 Page 14 of 15
et al. Healthcare costs of inflammatory bowel disease have shifted from
hospitalisation and surgery towards anti-TNFα therapy: results from the
COIN study. Gut. 2014;63(1):72–9.
54. (Statistiek) SNCBvd: Beroepsbevolking; kerncijfers naar geslacht en andere
kenmerken 1996–2014. 13 Februar 2015 edn; 2015.
55. Vesikari T, Dennehy P, Matson D, Itzler R, Dallas M, Goveia M, DiNubile M,
Heaton P, Lawrence J, Ciarlet M. Efficacy of Rotateq®, the pentavalent
rotavirus vaccine, between doses: potential benefits of early protection
[abstract]. Arch Dis Child. 2008;93:pw 70.
56. Vesikari T, Itzler R, Karvonen A, Korhonen T, Van DP, Behre U, Bona G, Gothefors
L, Heaton PM, Dallas M, et al. RotaTeq, a pentavalent rotavirus vaccine: efficacy
and safety among infants in Europe. Vaccine. 2009;28(3):345–51.
57. Vesikari T, Karvonen A, Ferrante SA, Ciarlet M. Efficacy of the pentavalent
rotavirus vaccine, RotaTeq(R), in Finnish infants up to 3 years of age: the
Finnish Extension Study. Eur J Pediatr. 2010;169(11):1379–86.
Bruijning-Verhagen et al. BMC Medicine  (2018) 16:168 Page 15 of 15
